

**INDOCO REMEDIES LIMITED**

Regd. Office : Indoco House, 166, CST Road, Kalina, Santacruz (East), Mumbai 400 098

Tel:+91-22-26541851/55 Fax:+91-22-26520787 Email:compliance.officer@indoco.com

Web:www.indoco.com CIN:L85190MH1947PLC005913

**UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2015**

**PART I**

(₹ In Lacs)

Sr. No.	Particulars	Quarter ended 30.06.2015 (Unaudited)	Quarter ended 31.03.2015 (Unaudited)	Quarter ended 30.06.2014 (Unaudited)	Year ended 31.03.2015 (Audited)
1	<b>Income from Operations</b>				
	(a) Gross Sales / Income from Operations	21,822	21,388	20,124	86,011
	(b) Excise Duty	(225)	(229)	(329)	(1,121)
	(c) Net Sales / Income from Operations (a-b)	21,597	21,159	19,795	84,890
	(d) Other Operating Income	743	(168)	68	474
	<b>Total Income from Operations (Net) (c+d)</b>	<b>22,340</b>	<b>20,991</b>	<b>19,863</b>	<b>85,364</b>
2	<b>Expenses</b>				
	(a) Cost of materials consumed	6,440	6,291	6,286	26,407
	(b) Purchases of stock-in-trade	1,415	1,389	1,148	5,363
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(212)	(831)	(177)	(1,925)
	(d) Employee Benefits expense	4,053	3,496	3,374	13,936
	(e) Depreciation and Amortisation expense	1,497	1,251	947	4,711
	(f) Research & Development Expense	648	745	429	2,167
	(g) Other Expenses	5,736	6,172	5,146	22,897
	<b>Total Expenses</b>	<b>19,577</b>	<b>18,513</b>	<b>17,153</b>	<b>73,556</b>
3	<b>Profit from Operations before Other Income, Finance Costs and Exceptional Items (1-2)</b>	<b>2,763</b>	<b>2,478</b>	<b>2,710</b>	<b>11,808</b>
4	Other Income	19	37	62	174
5	<b>Profit from Ordinary Activities before Finance Cost and Exceptional Items (3+4)</b>	<b>2,782</b>	<b>2,515</b>	<b>2,772</b>	<b>11,982</b>
6	Finance Costs	216	221	273	1,034
7	<b>Profit from Ordinary Activities after Finance Cost but before Exceptional Items (5-6)</b>	<b>2,566</b>	<b>2,294</b>	<b>2,499</b>	<b>10,948</b>
8	Exceptional Items	-	-	-	-
9	<b>Profit from Ordinary Activities before tax (7-8)</b>	<b>2,566</b>	<b>2,294</b>	<b>2,499</b>	<b>10,948</b>
10	Tax Expenses	539	419	495	2,667
11	<b>Net Profit from Ordinary Activities after tax (9-10)</b>	<b>2,027</b>	<b>1,875</b>	<b>2,004</b>	<b>8,281</b>
12	Extraordinary Items	-	-	-	-
13	<b>Net Profit for the period (11-12)</b>	<b>2,027</b>	<b>1,875</b>	<b>2,004</b>	<b>8,281</b>
14	Paid up Equity Share Capital (Face value ₹.2/- each)	1,843	1,843	1,843	1,843
15	Reserves excluding Revaluation Reserves as per Balance Sheet of Previous accounting year	-	-	-	49,995
16	<b>Earnings per share (before and after extraordinary items)</b> (of ₹ 2/- each) (not annualised):				
	(a) Basic	2.20	2.03	2.17	8.99
	(b) Diluted	2.20	2.03	2.17	8.99

**PART-II**

**SELECT INFORMATION FOR THE QUARTER ENDED 30TH JUNE,2015**

Sr. No.	Particulars	Quarter ended 30.06.2015 (Unaudited)	Quarter ended 31.03.2015 (Unaudited)	Quarter ended 30.06.2014 (Unaudited)	Year ended 31.03.2015 (Audited)
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>				
1	Public shareholding				
	- Number of Shares	375,51,706	375,51,671	376,01,399	375,51,671
	- Percentage of Shareholding	40.75	40.75	40.80	40.75
2	Promoters and promoter group shareholding				
	<b>a) Pledged/Encumbered</b>				
	- Number of shares	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-
	<b>b) Non-encumbered</b>				
	- Number of shares	545,98,649	545,98,684	545,48,956	545,98,684
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	59.25	59.25	59.20	59.25

Sr. No.	Particulars	3 months ended 30.06.2015
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	8
	Disposed of during the quarter	8
	Remaining unresolved at the end of the quarter	Nil

**Notes :**

1 The company has only one primary reportable segment of activity, namely, Pharmaceuticals.

**Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:**

(₹ In Lacs)

Net Sales and Income from Operations	Quarter ended 30.06.2015 (Unaudited)	Quarter ended 31.03.2015 (Unaudited)	Quarter ended 30.06.2014 (Unaudited)	Year ended 31.03.2015 (Audited)
India	13,217	12,973	12,800	53,208
Outside India	8,380	8,186	6,995	31,682
<b>Total</b>	<b>21,597</b>	<b>21,159</b>	<b>19,795</b>	<b>84,890</b>

2 The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.

3 The Company's stocks of samples and promotional items at its Central Warehouse at Indore were damaged due to fire on April 21, 2015. These stocks have been adequately insured. The Company has lodged a claim of ₹ 6.80 crore with the Insurance Company.

4 On April 06, 2015 the Company acquired the Clinical/Contract Research Organisation (CRO) division of Piramal Enterprises Ltd (PEL).

5 The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on July 30, 2015.

6 The statutory auditors of the company have carried out limited review of the financial results for the quarter ended June 30, 2015.

By Order of the Board  
For Indoco Remedies Ltd

Place : Mumbai  
Date : July 30, 2015.

**Suresh G Kare**  
**Chairman**